Micro1 is paying midsize companies $100,000 to $2 million for their internal data, and CEOs are cashing in before the AI data boom matures.

CEO Minami Maeda is running Phase 3 trials and targeting a 2028 FDA submission as photoimmunotherapy moves from Japanese clinics toward the world's largest market.

CuriousHagi's teardown of Apple's foldable reveals a gear-like hinge that may explain why screens crack in the same spot within hours.

Authentic Brands Group's suit over Presley's catalog signals a new front in AI copyright battles.

The CSRC green light lets Citigroup go solo in China's capital markets, just weeks before Xi and Trump meet at APEC.

The Oculus and Anduril founder is betting $200 million that 'elite working dogs' with advanced body armor will reshape the battlefield.

The Silicon Valley giant's cash flow went negative as AI costs surged, and it is issuing a new class of stock to raise capital.

A new University of Mississippi and Cornell review finds precision weed tools can replace chemicals and labor, yet adoption comes with serious financial and operational hurdles.

A federal judge tossed the case on procedural grounds after Ann Altman missed a medical exam and deadlines, clearing a legal overhang for OpenAI's chief.

Revolut, Halifax, and Emma went dark Tuesday as Google's London cloud region failed. Here's what it means for fintech's reliance on Big Tech infrastructure.

A final call from Beijing puts high-net-worth individuals on notice: declare offshore trust gains by October 22 or face penalties, with ripple effects for Hong Kong's wealth hub.

The U2 frontman reveals the band's pricing philosophy: affordable front rows, premium prices for the wealthy, as concert costs hit record highs and regulators circle Live Nation.